BTCY dividend history

Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors. Event: B

Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p

REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring. By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and

Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability. Company has all the

First Time in the Company's History REDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive free cash flow, a measure of financial health and another major milestone towards profitability. Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, explains: "While continuing on our mission to produce transformative healthcare technologies, we have demonstrated a strong commitment to growth and operational efficiency through innovation, automation and financial discipline, driving revenue and margins

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will de

The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today reports compelling financial and strategic advancements that will propel the company towards profitability by the end of Fiscal Q4. Biotricity is now on an accelerated trajectory to profitability due to growing revenues from sales and strategic partnerships, improving margins, and an earlier than expected milestone of achieving EBITDA positive on a go-forward cash b

REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease. Yet nearly half of U.S. counties do not have a practicing cardiologist, leaving patients in these areas with a roundtrip of over 85 miles to see a heart specialist versus 16 miles for those in a county with at least 1 cardiologist.

REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity's innovative cardiac monitoring solutions has never been more urgent. "This partnership marks a significant step forward in our mission to transform care delivery through advanced remote monitoring tec

REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform.The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters. The next version of the AI Cloud, currently under development, is anticipated to enhance the tech stack by

REDWOOD CITY, CA / ACCESSWIRE / July 11, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated."Our strategic initiatives and technological advancements have put us on a fast track to profitability," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "Calendar 2023 was transformative, characterized by a robust 25.2% increase in revenue, substantial margin improvements, and a significant reducti

REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states.Biotricity's cardiac monitoring solution is the only three-channel connected solution in the world. This unique technology results in superior diagnostics, reduced patient risk, and enhanced workflow efficiency, providing improved clinical outcomes while lowering overall healthcare costs. Additionally, it significantly increases provider revenue by five

REDWOOD CITY, CA / ACCESSWIRE / June 26, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its fourth quarter and fiscal year 2024 financial results and business update call on Thursday, June 27, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.Event: Biotricity Fourth Quarter and FY 2024 Financial Results and Business Update CallDate: Thursday, June 27, 2024Time: 4:30pm ET (1:30pm PT)Toll Free: 1-877-269-7751International: 1

REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease (CVD) every 1.5 seconds. In the U.S. alone, 127 million adults have at least 1 risk factor for heart disease, and 1 out of every 3 deaths is attributed to heart disease. To encourage preventative heart care and help reduce the prevalence of CVD, Biotricty is providing a limited-time discou

Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoYREDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.Revenue Growth is expected to exceed 24% YoYLoss from Operations is expected to decrease by over 40% YoYMargins are expected to improve by over 10% YoY"These developments are key indicators o

REDWOOD CITY, CA / ACCESSWIRE / June 4, 2024 / Biotricity Inc.] (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce that the majority of its existing Preferred A shareholders have converted 97% of all the preferred A shares into Restricted Common Stock, increasing their support and commitment to the Company."This recent conversion shows the growing enthusiasm our long-term shareholders have for the Company and their confidence in the execution and upcoming milestones of the company," remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.Recen

REDWOOD CITY, CA / ACCESSWIRE / May 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce plans for a revolutionary direct-to-consumer program, HeartSecure, to support the 127M Americans at risk for heart disease. HeartSecure offers the first-of-its-kind, home-based cardiac screening service, empowering individuals to proactively check their heart health from the comfort of their homes. When launched, this groundbreaking home-based cardiac screening service will be a significant milestone for Biotricity, positioning the comp

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2024 / Biotricity Inc. (NASDAQ:BTCY), a pioneering Technology-as-a-Service (TaaS) company dedicated to delivering top-of-the-line medical diagnostic and consumer healthcare solutions, announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%. This will translate to a revenue increase of up to 10% from sales to existing customers over the course of fiscal 2025. Biotres Pro is also capturing the attention of new customers. The initial production run of Biotres Pro has

REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity's technology suite.This collaboration comes at the heels of another recent pilot, shortly after Biotricity established strategic partn

REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. The pilot program will demonstrate the value of Biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network."Our partnerships with leading Group Purchasing Organizations (GPOs) have rapidly enhanced our visibility and market reach, and this latest pilot program is a direct result of that im

REDWOOD CITY, CA / ACCESSWIRE / April 2, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue. Alzheimer's, Parkinsons, and other dementias are just a few such conditions that lead to increased cardiovascular risk. Many of these patients are screened late, leading to an i

REDWOOD CITY, CA / ACCESSWIRE / March 28, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership with yet another leading Group Purchasing Organization (GPO). GPOs streamline purchasing processes for medical providers and systems. With this latest partnership, Biotricity's GPO partners collectively manage the buying needs of 9 out of every 10 hospitals in the U.S. Moreover, they wield immense purchasing power, totaling $264 billion. With these strategic alliances, Biotricity is p

REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the most highly anticipated charity concerts for healthcare access and awareness. Experience the rhythm of life like never before at the Health Aid Africa charity concert, where the thrill of music meets the heart of wellness, thanks to a pioneering partnership with Biotricity Inc. Set against the backdrop of the world's most renowned stadium, this event offers more than just spectacular musical acts-it pre

REDWOOD CITY, CA / ACCESSWIRE / March 5, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced its partnership with another of the nation's top Group Purchasing Organizations (GPOs). This strategic move solidifies Biotricity's presence in the healthcare landscape and broadly expands market access for the Company in 2024. Biotricity now has access to over half the hospitals in the US, with a network of over 3,000 hospitals, through these two major GPOs which are responsible for over $160 billion in purchasing power."Biotricity's relationship with yet another leading GPO marks a significant

Well Positioned to Enter US $1.56 Billion Canadian Cardiology Devices MarketREDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, proudly announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering US$21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost, the approval of Biotres by Health Canada comes at an opportune time.Biotricity's mission to develop innovative diagnostic solutions that engage and empower individua

REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.Event: Biotricity Third Quarter FY 2024 Financial Results and Business Update CallDate: Wednesday, February 21st Time: 4:30pm ET (1:30pm PT)Toll Free: 877-497-9071International: +1

Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakevenManagement to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024REDWOOD CITY, CA / ACCESSWIRE / February 14, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency.For the Third Quarter of Fiscal Year 202

Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platformCompany has analyzed over 360 Billion heartbeats and helped diagnose over 200,000 patientsCompany is now focused on building predictive AI models to support earlier diagnoses and interventionsExisting technologies are used in 500+ centers across the United StatesREDWOOD CITY, CA / ACCESSWIRE / January 23, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced the expanding development of its future Cardiac AI Cloud platform. The new platform is

Biotricity improves margins while lowering selling expenses and operating lossesREDWOOD CITY, CA / ACCESSWIRE / November 10, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.Event: Biotricity Second Quarter FY 2024 Financial Results and Business Update CallDate: Tuesday, Nov

Company further expands its current product portfolio, making it the most comprehensive Remote Patient and Cardiac Monitoring portfolio globally.Company developed Biotres Pro with critical capability of cellular backup for connectivityRecently filed a patent application for its Biotres device as it seeks to redefine the cardiac care landscapeREDWOOD CITY, CA / ACCESSWIRE / October 31, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced their expansion of the current Biotres product platform. The new product, known as Biotres Pro, adds cellular backup for offline connectivity in addition

REDWOOD CITY, CA / ACCESSWIRE / October 10, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitoring sector of consumer healthcare, today announced its patent filing for the company's Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine's Best Inventions of 2022 stands as a "game changer" in the industries of personal heart and remote lifestyle monitoring. This patent safeguards Bioheart's exclusive 3-view dry-contact technology, advanced sensor system, unique design, and compact form factor - a combination that's never been seen in the con

This release corrects and replaces the headline in the the release that was disseminated October 3, 2023.The reason for this correction is to fix the title which previously stated "patient" rather than the correct word, "PATENT"REDWOOD CITY, CA / ACCESSWIRE / October 4, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device. Biotres is a cutting-edge invention that marks a significant advancement in remote patient monitoring and cardiac care. This filing expands the Company's IP portfolio while increasing mark

REDWOOD CITY, CA / ACCESSWIRE / October 3, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device. This patent protects Biotres' proprietary 3 channel technology, multiple sensors, architecture and compact form factor, a combination that has never been done before. Up until now, compact devices have lacked multiple channels, reducing the quality of diagnosis. Biotres is a cutting-edge invention that marks a significant advancement in remote patient monitoring and cardiac care. This filing expands the Company's

Biotricitys New Digital Presence Reflects Commitment to Innovation in the Healthcare Space.REDWOOD CITY, CA / ACCESSWIRE / September 13, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions.Biotricity has built a suite of solutions that combine connectivity, smart analytics, AI and cutting-edge cloud technologies. The solutions support individuals and patients from diagnostics to disease management depending on the solution utilized:Bioflux: Bioflux is a superior

Corporate Impact Report concluded better patient outcomes and substantial cost savings, thus accelerating Company's sales growthREDWOOD CITY, CA / ACCESSWIRE / August 30, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate.Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "The recent acceleration in revenue gains, increasing sales of our remote cardiac monitoring devices, and ramp up of subscription-ba

REDWOOD CITY, CA / ACCESSWIRE / August 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its First Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, August 15, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.Event: Biotricity First Quarter FY 2024 Financial Results and Business Update CallDate: Tuesday, August 15th Time: 4:30pm ET (1:30pm PT)Toll Free: 877-405-1216International: +1 201-689-8

Company to report robust performance improvements in its operating metricsRecord Q1-FY2024 recurring revenue growthSignificantly higher margins on technology fees compared to blended marginsStrong control over sales and technology expenses through automation and AIREDWOOD CITY, CA / ACCESSWIRE / August 11, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitoring sector of consumer healthcare, is pleased to report that its business continues to demonstrate strong fundamentals that are propelling the Company towards profitability. Biotricity anticipates announcing its best-quarter yet, for the firs

REDWOOD CITY, CA / ACCESSWIRE / July 21, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing Biotricity that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.About Biotricity Inc.Biotricity, Inc. is reforming the healthca

Company estimates Q1-FY24 revenue to grow YOY by over 40%Recurring technology fees, customer second-device sales, continue to trend higherREDWOOD CITY, CA / ACCESSWIRE / July 6, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024.For the first fiscal quarter ended June 30, 2023, the Company expects to report an approximate increase in revenue which represents growth of over 40% YOY from the corresp

REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. ("Biotricity" or the "Company") (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023.The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.At the effective time of t

The Company recently announced reaching a record $13 million annualized revenue run rate in April 2023REDWOOD CITY, CA / ACCESSWIRE / June 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, announced that it will host its Fiscal Year 2023 Financial Results and Business Update Call on Friday, June 30, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.Event: Biotricity FY 2023 Financial Results and Business Update CallDate: Friday, June 30thTime: 4:30pm ET (1:30pm PT)Toll Free: 877-405-1216I

Company's proprietary AI technology allows for expansion into predictive monitoring and new disease profilingThe New England Journal of Medicine article cites AI and its potential for increased healthcare efficiency and insightsREDWOOD CITY, CA / ACCESSWIRE / May 23, 2023 / Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today commented on contributions of artificial intelligence (AI) and machine learning and its transformative nature for healthcare.As stated in The New England Journal of Medicine, March 30, 2023 article entitled, Artificial Intelligence in Medicin

Corporate Impact Report concluded better patient outcomes and substantial cost savings for patients using Company's devicesREDWOOD CITY, CA / ACCESSWIRE / May 16, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $13 million annualized revenue run rate in April -- further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "In collaboration with our affiliated cardiologists, our solutions-focused business model is proving itself to provide superi

REDWOOD CITY, CA / ACCESSWIRE / April 19, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $12 million annualized revenue run rate in March 2023.Based on preliminary month-to-date results and internal projections, the Company remains excited regarding potential top line revenue growth in April and the current quarter (Q4FY23) as it maintains optimized investment in R&D, sales and marketing. The Company attributed its strengthening financials to the growing sales of its product line of remote cardiac monitors spanning consumers to cardiologists, the ramp up of

"Inducing Better Patient Outcomes, Substantial Cost Savings"REDWOOD CITY, CA / ACCESSWIRE / April 11, 2023 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, has released its first Corporate Impact Report- revealing that the company's remote, clinical-grade diagnostic devices are inducing "better patient outcomes and substantial cost savings" across the nation.Presenting new data, the report highlights specific examples of Biotricity's impact on "reforming the healthcare market by bridging the gap between effective remote diagnostics, remote patient monitoring and chronic care management."The report, for

REDWOOD CITY, CA / ACCESSWIRE / January 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists' patient use - Bioflux® and BiotresTM.The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients.Commenting on the agreement, Biotricity Founder, Chairman and CEO Waqaas Al-Siddiq, Ph.D., sa